Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Aiolos Bio debuts with $250M and ex-Gyroscope CEO to tackle severe asthma
A striking trend throughout 2023 has been the gravitational pull of significant funding toward promising biotech endeavors. This theme is ...
AxoSim acquires Vyant’s organoid tech for brain disorder research
AxoSim, a New Orleans-based drug discovery biotech, has successfully completed the acquisition of the neuroscience research assets from Vyant Bio’s ...
OrbiMed raises $4.3B for 3 funds to back biotech startups
OrbiMed, a major global financier of biopharmaceutical companies, has successfully amassed $4.3 billion, earmarked for investment in emerging healthcare and ...
BrainStorm cuts 30% staff, eyes ALS cell therapy approval
BrainStorm Cell Therapeutics has chosen an unconventional route in response to its recent setback in securing approval. While the decision ...
Indivior ends Suboxone saga with $385M antitrust deal
Indivior, the manufacturer of Suboxone, has taken a significant step towards closing the chapter on years of antitrust litigation related ...
Pfizer Faces Backlash for Raising Price of Covid Drug Paxlovid
Following Pfizer’s announcement to increase the cost of its COVID-19 treatment drug, Paxlovid, for the next year, the AIDS Healthcare ...
Dupixent Fails to Win FDA Approval for Hives Disorder, Needs More Data
Regeneron and Sanofi have faced an unexpected hurdle in their pursuit of regulatory approval for Dupixent, a monoclonal antibody aimed ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
Pfizer’s Penbraya: First vaccine to prevent all five types of meningitis gets FDA approval
Pfizer has secured a significant regulatory victory in the race to introduce the first five-pronged meningitis vaccine in the United ...
Samsung BioLogics faces FDA scrutiny over data integrity and quality issues at Korean plant
The FDA recently issued manufacturing alerts, targeting high-flying companies Samsung Biologics and Nectar Lifesciences. For Samsung Biologics, a notable player ...
Tremfya clears psoriasis in people of color, first study of its kind shows
The journey to improved treatments for psoriasis, a challenging skin condition, has been long and complex. Despite advances, some patient ...
Eli Lilly sues fake Mounjaro sellers for trademark infringement and false advertising
Eli Lilly, the pharmaceutical giant, is intensifying its legal efforts to combat unauthorized versions of its popular diabetes drug, Mounjaro. ...
J&J’s dengue pill shows antiviral activity in human trial, could prevent millions of infections
Amidst Johnson & Johnson’s strategic restructuring in the infectious disease and vaccine divisions, one resilient contender has emerged. JNJ-1802, an ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
Nkarta’s breakthrough cell therapy for lupus gets FDA approval after showing promise in cancer treatment
In a groundbreaking development, Nkarta is pushing the boundaries of cell therapy beyond the realm of cancer. The FDA has ...
FDA Clearance for Micromate: A tiny robot that can perform needle biopsies with CT imaging
Interventional Systems, the brains behind a compact yet powerful robotic marvel, is set to leave a profound mark in the ...
Pfizer agrees to pay $300,000 to resolve gender pay bias claims at NYC HQ
Pfizer has agreed to a $2 million settlement to resolve allegations made by the US Department of Labor, which claimed ...
Sanofi launches soccer program for homeless people in Korea with ‘Dream’ team
Sanofi’s South Korea branch organized an indoor soccer game known as futsal to address the social isolation experienced by homeless ...
BMS and Halozyme announce positive results for subcutaneous Opdivo in cancer patients
Following the discontinuation of an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb (BMS) has achieved success with a more ...
Fake Ozempic products seized in EU and UK, Novo Nordisk warns
As Novo Nordisk grapples with the challenges posed by illicit sales of semaglutide, authorities in the UK and Europe have ...
Roche unveils its blood cancer strategy after COVID-19 boost
While Roche has seen a decline in COVID-19 drug sales after the pandemic boom, the company is experiencing a resurgence ...
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
Takeda’s Alofisel fails to meet primary endpoint in phase 3 trial for Crohn’s disease complication
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
Avania acquires two medtech CROs, broadens its global services and expertise
Avania, a medtech-focused Contract Research Organization (CRO) headquartered in the Netherlands, has extended its industry expertise through the strategic acquisitions ...
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
Roche abandons oral drug for eye disease after phase 2 failure, shifts focus from solid tumor bispecifics
Roche’s ambitious quest to develop an oral treatment for diabetic retinopathy has faced a setback, as the company decided to ...
Bimzelx, a potential blockbuster for psoriasis, clears FDA approval after resolving manufacturing issues
UCB’s long-awaited FDA approval for its psoriasis therapy, Bimzelx (bimekizumab), has finally arrived, ending a journey marked by manufacturing setbacks. ...
Basilea buys clinical-stage antifungal from Eisai, advances its anti-infective strategy
Basilea Pharmaceutica is making a strategic move to bolster its anti-infective pipeline, this time with a $2 million investment in ...
Zilbrysq, A Complement C5 Inhibitor For Myasthenia Gravis, Gets FDA Approval As UCB’s Second Drug For The Rare Disease
UCB is celebrating an impressive streak of FDA approvals, securing the green light for both the plaque psoriasis treatment Bimzelx ...
